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Abstract
Background: Primordial ovarian follicles, which are often present in the ovaries of premature ovarian failure (POF) patients
or are cryopreserved from the ovaries of young cancer patients who are undergoing gonadotoxic anticancer therapies,
cannot be used to generate mature oocytes for in vitro fertilization (IVF). There has been very little success in triggering
growth of primordial follicles to obtain fertilizable oocytes due to the poor understanding of the biology of primordial
follicle activation.
Methodology/Principal Findings: We have recently reported that PTEN (phosphatase and tensin homolog deleted on
chromosome ten) prevents primordial follicle activation in mice, and deletion of Pten from the oocytes of primordial follicles
leads to follicular activation. Consequently, the PTEN inhibitor has been successfully used in vitro to activate primordial
follicles in both mouse and human ovaries. These results suggest that PTEN inhibitors could be used in ovarian culture
medium to trigger the activation of primordial follicle. To study the safety and efficacy of the use of such inhibitors, we
activated primordial follicles from neonatal mouse ovaries by transient treatment with a PTEN inhibitor bpV(HOpic). These
ovaries were then transplanted under the kidney capsules of recipient mice to generate mature oocytes. The mature
oocytes were fertilized in vitro and progeny mice were obtained after embryo transfer.
Results and Conclusions: Long-term monitoring up to the second generation of progeny mice showed that the mice were
reproductively active and were free from any overt signs or symptoms of chronic illnesses. Our results indicate that the use
of PTEN inhibitors could be a safe and effective way of generating mature human oocytes for use in novel IVF techniques.
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Introduction
In the mammalian ovary, the original pool of primordial follicles
is the source of all eggs that will be produced over the entire course
of the organism’s reproductive life. To maintain the normal length
of the female’s reproductive life, the majority of primordial follicles
must remain in a quiescent state for later use [1–4]. A highly
controlled, but poorly understood, mechanism ensures that only
a limited number of primordial follicles are activated at any given
time to provide a steady supply of fertilizable oocytes that are
available at regular intervals. However, during the pathological
conditions such as premature ovarian failure (POF), there is an
accelerated depletion of primordial follicles [5,6]. Recently, the
number of POF patients has increased dramatically due to the
increasing number of survivors of childhood and adolescent
cancers whose primordial follicles have been destroyed by toxic
anticancer therapies [7].
Primordial follicles are located in the cortical region of the
ovaries and are the most abundant type of follicles at any stage of
the female’s life [8]. Because primordial follicles are resistant to
freezing and thawing processes, cryopreservation of ovarian
cortical tissue prior to gonadotoxic therapies has become an
attractive fertility preservation technique [9]. Moreover, ovarian
tissue cryopreservation remains the only fertility-preserving option
for children because neither ovarian stimulation and collection of
mature oocytes nor collection of fertilized embryos is feasible [7].
Thus, over the past decade, an increasing number of fertility
centers have been cryopreserving ovarian tissues prior to
gonadotoxic therapies, and much of this increase is coming from
prepubescent patients [10]. The ovaries of adult POF patients may
still contain certain numbers of primordial follicles, but these small
follicles do not express the receptor for follicle stimulating
hormone (FSH). Thus these follicles cannot be used with current
in vitro fertilization (IVF) techniques in which FSH stimulation of
the follicles is the first step in obtaining fertilizable eggs [2].
Nevertheless, ovarian cortical tissue from these women can still be
collected without hyperstimulation and without regard to their
menstrual cycle stage. Theoretically, it is possible to use these
primordial follicles for the purpose of in vitro maturation (IVM) to
obtain the mature, fertilization-competent oocytes that are re-
quired to restore fertility to these patients [3,11].
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produce fertilizable oocytes in vitro, this technique has not been
successful due to the poor understanding of the growth regulation
of these follicles. Recent work from our lab has revealed that
phosphatase and tensin homolog deleted on chromosome ten
(PTEN), a negative regulator of phosphatidylinositol 3 kinase
(PI3K), functions in oocytes to specifically suppress the primordial
follicle activation [12,13]. This finding clearly indicated the
possibility of treating ovarian tissues with PTEN inhibitors to
activate primordial follicles and allow them to grow to a stage
where the follicles can respond to FSH.
Accordingly, PTEN inhibitor has been shown to effectively
activate primordial follicles both in neonatal mouse ovaries and in
human ovarian cortical tissues. These activated follicles sub-
sequently developed into mature follicles and generated fertilizable
oocytes after transplantation into the kidney capsules of ovariec-
tomized recipient mice [14]. Although live mice had been
obtained upon fertilization and embryo transfer, long term follow
up on the fertility and general health status of the offspring was not
performed.
Stringent testing of the safety of PTEN inhibitors must be
carried out before they can be used for primordial follicle culture
in humans. With the aim of testing the safety of PTEN inhibitors
for the generation of fertilizable eggs, we activated primordial
follicles in neonatal mouse ovaries by treatment with bpV(HOpic)
and then transplanted the ovaries under the kidney capsules of
recipient mice to obtain mature oocytes. Mature oocytes were
fertilized in vitro and, upon embryo transfer, healthy, fertile
progeny mice were obtained. The fertility of second-generation
progeny mice also appeared to be unaffected and these mice had
no obvious health issues. Moreover, despite PTEN’s known roles
in tumor suppression [15,16] and metabolic regulation [17] in
various tissues, the mice obtained from this novel form of IVF did
not show any overt signs or symptoms of chronic illnesses over
a prolonged testing period. Thus, the use of PTEN inhibitors
increases the yield of mature mouse eggs that can be fertilized to
generate healthy offspring, and our results show that PTEN
inhibitors have significant clinical potential for generating healthy
and fertilizable human oocytes.
Results
Enhanced Follicular Growth by Transient PTEN Inhibition
To determine the effect of transient PTEN inhibition on
primordial follicle activation and subsequent follicular develop-
ment, we removed both ovaries from postnatal day (PD) 3 mice.
One of the ovaries was treated with bpV(HOpic) for 24 h and then
transplanted under one side of the kidney capsules of an
ovariectomized adult recipient mouse. As a control, the other
ovary was cultured without bpV(HOpic) and was transplanted
under the other kidney capsule in the same recipient mouse. We
found that the bpV(HOpic)-treated ovaries were significantly
larger than the untreated control ovaries (Fig. 1A). Moreover,
ovarian histology showed that the treated ovaries had more
follicles at preovulatory stages than untreated control ovaries
(Fig. 1B).
In Vitro Fertilization and Embryo Transfer to Obtain Live
Pups
We isolated mature oocytes from the bpV(HOpic)-treated
ovaries that had been transplanted under the kidney capsules of
recipient mice. After 24 h of in vitro fertilization with donor sperm,
the oocytes developed into two-cell stage embryos (Fig. 2A). A total
of 149 two-cell embryos were transferred to the oviducts of 10
pseudopregnant recipient mice. We obtained 29 healthy, first
generation (F1) pups (Fig. 2B) that grew into healthy adults. These
results show that the use of a PTEN inhibitor for activation of
primordial follicles does not affect the quality of the resulting eggs
because the eggs can be fertilized and develop into adult mice.
Effects of Treatment with bpV(HOpic) on the Fertility and
Health of the First and Second Generation Progeny Mice
To assess the possible impairment on the reproductive capacity
of the progeny mice derived from bpV(HOpic)-treated oocytes, F1
males and F1 females were bred with either wild type (B6/C57J or
B6D2F1 as indicated in the figure legends) mice or with their F1
siblings (Fig. 3). During an observation period lasting from 13 to
40 weeks of age, breeding between F1 females and B6/C57J males
regularly produced second generation (F2) litters with an average
litter size of 7.863.3 pups. Similarly, during the same testing
period, breeding between B6D2F1 females and the F1 males
regularly produced F2 generation litters with an average litter size
of 8.063.1 pups (Fig. 3). To determine the fertility of breeding
pairs when both parents were derived from the oocytes exposed to
bpV(HOpic), we also bred F1 males with F1 females. We found
that during the testing period breeding between F1 males and F1
females regularly generated F2 litters with an average litter size of
7.562.9 pups (Fig. 3). Thus, the F1 mice born as a result of IVF
with oocytes treated with the PTEN inhibitor bpV(HOpic) were
reproductively sound.
We next assessed the fertility of the second generation mice by
recording the number of pups per litter produced by breeding
between F2 females and F2 males. These F2 mice were obtained
from the breeding between F1 females and B6/C57J males.
Throughout an observation period lasting from 10 to 24 weeks of
age, breeding between F2 females and F2 males produced third
generation (F3) pups with an average litter size of 7.861.3 mice
(Fig. 3). These results show that the transient treatment with
bpV(HOpic), at a dose that is sufficient to trigger primordial
follicle activation in neonatal mouse ovaries, does not impair the
fecundity of the F1 and the F2 progenies.
Moreover, despite the known roles of PTEN as a tumor
suppressor [15,16] and a metabolic regulator [17], both the F1
(the first batch of these mice have been obtained over a year ago)
and the F2 mice did not develop any tumors or other signs or
symptoms of chronic illnesses.
Fertility and Overall Health Status of Female Mice
Injected with bpV(HOpic)
To gain more insight into the possible toxicity of bpV(HOpic),
PD5 female mice of strain CD-1 were directly injected with this
inhibitor. Injection was repeated again at PD18. One group of
female mice was injected with a low dose (150 ng/g body weight)
and the other group with a high dose (300 ng/g body weight) of
bpV(HOpic). During a testing period from 10 to 23 weeks of age,
both the low and high dose PTEN-inhibitor injected females
regularly produced F1 litters with slightly higher numbers of pups
than the control mice injected only with PBS (Fig. 4A). These mice
also failed to develop tumors or other signs of chronic illnesses.
We extended our fertility and health status monitoring to the F1
mice that were produced by mice injected with both low and high
doses of bpV(HOpic). Throughout the testing period from 10 to 23
weeks of age, breeding between F1 males and F1 females produced
healthy F2 generation litters that were comparable in size to those
produced by the control breeding pairs (Fig. 4B). Moreover, all of
the bpV(HOpic)-injected mice and their F1 progeny mice were
healthy and did not show any overt signs of chronic illness.
Healthy Pups from Pten Inhibitor Treated Ovaries
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39034Discussion
The development of an in vitro system for producing fertilization-
competent oocytes from primordial follicles would revolutionize
the current methods of treating female infertility. However, there
has been only limited success in culturing primordial follicles to
obtain mature oocytes [18] due to our limited knowledge of the
biology of folliculogenesis, especially of how primordial follicles are
activated from their dormant state [3]. Treatment of mouse
ovaries and human cortical tissues with the PTEN inhibitor led to
activation of primordial follicles in both mice and humans, which,
upon prolonged transplantation under the kidney capsule of
recipient mice, yielded significantly higher numbers of fertilizable
oocytes than untreated controls [14]. These results clearly showed
that PTEN inhibitors could indeed be used to activate primordial
follicles in mice and human ovaries.
PTEN is a tumor suppressor that is mutated in many human
tumors [15]. Similarly, conditional deletions of Pten from
primordial germ cells, the prostate, the pancreas, mammary
epithelium, thyrocytes, the liver, or the smooth muscle cell lineage
in mice have been reported to be associated with teratomas,
prostatic cancers, pancreatic cancers, breast cancers, thyroid
cancers, cholangiocellular carcinomas, and leiomyosarcomas,
respectively [reviewed in reference 3]. PTEN is also emerging as
a regulator of metabolic pathways [17]. These potential negative
Figure 1. Enhanced follicular development by transient treatment of neonatal mouse ovaries with the PTEN inhibitor bpV(HOpic).
(A) Comparison between the sizes of treated and control ovaries transplanted under the kidney capsules. One ovary from a PD3 mouse was cultured
for 24 h with 1 mM bpV(HOpic) and another ovary was cultured without bpV(HOpic) and then transplanted under the capsule of each kidney of the
same ovariectomized recipient as described in Materials and Methods. Ovaries that were treated with bpV(HOpic) before transplantation grew bigger
than the non-treated control ovaries. K represents kidney tissue from the recipient, O represents the transplanted ovary, and the ovarian border is
outlined by dashed circles. Scale bar=1 mm. (B) Morphological analysis of treated and control ovaries excised from the kidney capsules. Ovaries from
PD3 mice were cultured for 24 h with or without 1 mM bpV(HOpic) before transplantation under each kidney capsule of the same ovariectomized
recipient as described in Materials and Methods. One day after the transplantation, recipient mice were treated daily with 2 IU of pregnant mare
serum gonadotropin for 18 days. Fourteen hours before being killed, the mice were treated with 5 IU of human chorionic gonadotropin. Ovaries were
excised from the kidney capsules and embedded in paraffin, and serial sections of 8 mm thickness were prepared and stained with hematoxylin. A
larger number of antral follicles were observed in the bpV(HOpic)-treated ovaries (arrows) than in the control ovaries. The experiments were repeated
at least 4 times, and 5 mice were used each time. Scale bar=250 mm.
doi:10.1371/journal.pone.0039034.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39034Figure 2. In vitro fertilization and birth of live pups after embryo transfer into the recipient mice. (A) Fertilization of mature oocytes
obtained from the PTEN inhibitor-treated ovaries. Ovaries from PD3 mice were cultured for 24 h with 1 mM bpV(HOpic) before transplantation under
the kidney capsules of ovariectomized recipient mice as described in the Materials and Methods. One day after the transplantation, recipients were
treated daily with 2 IU of pregnant mare serum gonadotropin for 18 days. After 18 days, the recipient mice were injected with 5IU human chorionic
gonadotropin and the grafted ovaries were collected 14 h later. MII stage oocytes were fertilized in vitro as described in the Materials and Methods.
After 24 h post fertilization, embryos had reached the two-cell stage. Scale bar=25 mM. (B) Birth of live pups after embryo transfer. In vitro fertilized
two-cell embryos were transferred into the oviducts of pseudopregnant surrogate mothers that had been prepared as described in the Materials and
Methods.
doi:10.1371/journal.pone.0039034.g002
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tumorigenesis and metabolic illnesses such as diabetes, hyperten-
sion, and cardiovascular disease in the mice that are generated by
the fertilization of oocytes obtained from PTEN inhibitor-treated
ovaries. However, a comprehensive analysis of the fertility and
overall health of mice derived from this technique has not yet been
reported.
In the current study, we have cultured neonatal mouse ovaries
with the PTEN inhibitor bpV(HOpic) and shown that the use of
this compound can stimulate primordial follicle activation and
results in the production of a higher number of mature follicles
than in controls. The mature oocytes can be fertilized, and live
mice can be obtained upon embryo transfer. We also showed that
the progeny male and female mice are reproductively sound and
healthy.
Despite the known antitumorigenic effect of PTEN in several
tissue types, neither the oocyte specific [12] nor the granulosa cell
specific [19] deletion of Pten led to ovarian tumor formation.
Moreover, short term treatment of human [14, and our un-
published data] or bovine (our unpublished data) ovarian tissues
with PTEN inhibitor, followed by long term transplantation under
the kidney capsules of severe combined immunodeficient (SCID)
mice did not lead to any tumor formation in the graft or in the
recipient mice. These results indicate that PTEN has cell and
tissue-specific functions and in the ovary it specifically acts as
a suppressor of primordial follicle activation. In this regard, we
have also shown that the deletion of Pten from oocytes does not
affect the development of already growing follicles [13].
Successful in vitro culture of follicles for the production of mature
oocytes that are competent for fertilization would be a major step
forward in the development of treatment options for adult women
and young girls facing potentially gonadotoxic diseases or
treatments. In prepubescent girls who suffer from POF, ovarian
cryopreservation is the only fertility-preserving option because
neither ovarian stimulation and collection of mature oocytes nor
obtaining fertilized embryos is feasible [9]. Even for adult POF
patients who may still have large numbers of primordial follicles;
such in vitro culturing techniques from ovarian cortical tissue would
avoid the issues of menstrual cycles and requirements for
hyperstimulation by hormones. Using this technique, hundreds
of primordial follicles can be cryopreserved in a single procedure
that can be performed immediately without causing delays in
cancer treatment [20]. More importantly, in contrast to fully
developed oocytes, primordial follicles are less susceptible to cryo-
damage and are thus more easily preserved [21].
Cryopreserved ovarian tissue has been successfully reimplanted
orthotopically and heterotopically to enhance follicular growth
and obtain mature follicles [22,23]. However, for cancer-POF
patients the potential risk of reintroduction of cancer cells has
always remained a concern during reimplantation [7]. In this
regard, our successful use of a PTEN inhibitor for follicular
activation is a very promising step towards obtaining a large
number of mature oocytes in vitro. In the current study, the
inhibitor-treated ovaries were transplanted under the kidney
capsules of recipient mice to provide the optimum in vivo
conditions for the growing follicles. Human follicular develop-
ment, however, is a lengthy process that requires several months in
vivo for mature follicles to develop [2]. Therefore, for the
translation of this technique into humans, it is important to
develop a culturing method that can support the full maturation of
the activated follicles in vitro.
In summary, we have shown that transient inhibition of PTEN
is a novel way of triggering the activation of primordial follicles,
which, under favorable growth conditions, can develop into
mature and fertilizable oocytes. These oocytes can then be used to
obtain fertile and healthy progeny mice. Thus, our findings have
significant clinical implications for treating female infertility by
generating healthy, mature oocytes for in vitro fertilization.
Materials and Methods
Mice
Mice were obtained from Charles River Laboratories and were
housed under controlled environmental conditions with free access
to water and food. Illumination was on between 0600 and 1800 h.
Ovaries of PD3 female mice were used for in vitro culture with
bpV(HOpic) and transplantation under the kidney capsules of
adult female mice of the same strain. Animals were anesthetized by
intraperitoneal injection with 2,2,2-tribromoethanol (0.4 mg/g
body weight; Avertin, Sigma).
Ethics Statement: Experimental protocols were approved by the
regional ethical committee of the University of Gothenburg,
Sweden.
In Vitro Culture of Neonatal Mouse Ovary
Paired ovaries from PD3 B6D2F1 female mice were excised and
washed three times in M2 medium (Sigma) supplemented with
3 mg/mL BSA (Sigma). Ovaries were cultured on Millicell inserts
(Millipore) in 24-well plates (Nunc, Denmark) with 300 mLo f
culture medium. The culture medium consisted of a-MEM (Life
Technologies) supplemented with 3 mg/mL BSA, 50 U/mL
penicillin (Invitrogen), 50 mg/mL streptomycin (Invitrogen) and
2 mM L-glutamine (Invitrogen). From a given donor, one ovary
served as the control and the other was treated with 1 mM
bpV(HOpic) (Calbiochem). Ovaries were cultured for 24 h at
37uC in a humidified atmosphere of 5% CO2.
Ovary Transplantation
The recipient mice were anesthetized and kidneys exteriorized
through a dorso-horizontal incision. A small hole was torn in the
kidney capsule using a 28 G needle. A control ovary was inserted
Figure 3. Fertility measurement of the first and second
generation progeny mice. The F1 female and F1 male mice that
were obtained by embryonic transfer were bred with B6/C57J male and
B6D2F1 female mice, respectively. Fertility was also checked by
breeding F1 males and F1 females. During the testing period, the mice
regularly produced normal-sized F2 generation litters at normal
intervals. To determine the fertility of the second generation mice, F2
females were bred with F2 males. n= number of breeding pairs used.
doi:10.1371/journal.pone.0039034.g003
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inserted into the other kidney capsule of the same recipient mouse.
In order to increase endogenous gonadotropin levels, both ovaries
of the recipient mice were removed by cauterization at the top of
the uterine horns. Finally, the body wall incisions and skin were
closed. One day after the transplantation, recipients were treated
daily with 2 IU of pregnant mare serum gonadotropin (PMSG)
(Sigma) for 18 days.
Histological Analysis of Ovary
Transplanted ovaries were excised from the kidney capsules of
recipient mice, fixed in 4% paraformaldehyde, dehydrated, and
embedded in paraffin. The paraffin-embedded ovaries were
serially sectioned at 8 mm thickness and stained with hematoxylin
for morphological observation.
IVF and Embryo Transfer
Eighteen days after transplantation, the recipient mice were
injected with 5 IU human chorionic gonadotropin (hCG) (Sigma)
and the grafted ovaries were collected 14 h later in M2 medium.
Ovaries were then punctured to release the oocytes into M2
medium containing 0.1% hyaluronidase (Sigma). The maturation
stages of the oocytes were assessed and MII stage oocytes were
used for IVF. Sperm were collected from 14 to16-week-old
B6D2F1 male mice in human tubal fluid (HTF) medium
(Millipore) and incubated under mineral oil (Sigma) for 1 h at
37uC in a humidified atmosphere of 5% CO2. The MII stage
oocytes were placed in 500 mL drops of HTF medium with the
sperm (2.5 6 10
5/mL) and incubated for 5 h at 37uC with 5%
CO2. After fertilization, the embryos were washed in KSOM
medium (Millipore) to remove the excess sperm and then cultured
Figure 4. Fertility measurement of the female mice directly injected with bpV(HOpic). (A) Weekly comparison of the cumulative number
of pups for the low dose bpV(HOpic)-injected mice (n=2, blue bars), high dose-injected mice (n=2, red bars) and control mice (n=2, black bars). All
mice had been bred with CD-1 strain males. (B) Weekly comparison of the cumulative number of pups produced by breeding the F1 mice. Breeding
between F1 males and F1 females produced by low dose-injected females (n=2, red bars), breeding between F1 males and F1 females produced by
high dose-injected females (n=2, green bars) and breeding between F1 males and F1 females produced by PBS-injected females (n=2, black bars).
n=number of breeding pairs used.
doi:10.1371/journal.pone.0039034.g004
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a humidified atmosphere of 5% CO2. Two-cell embryos were
transferred to the oviducts of pseudopregnant foster mothers.
Eight to 10-week-old B6/CBA (F1) female mice were mated with
vasectomized males of the B6D2F1 strain to prepare the foster
mother before the embryo transfer.
PTEN Inhibitor Injection in Mice
Female CD-1 mice were intraperitoneally injected with
bpV(HOpic) (150 or 300 ng/g body weight) at 5 and 18 days
after birth. The fertility of the treated females was assessed by
counting the numbers of pups produced after mating with males of
the same strain. To check the fertility of the F1 mice, male and
female siblings were mated and the numbers of pups were
counted.
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